Morning Report | Hormuz risk whips crude, AI leaders face dilution—rotation test for U.S. megacaps
$QQQ AI leaders hit by dilution $USO Hormuz risk whips crude $SPY immigration funding cleared House $FXI PPI accelerates, CPI softens $TLT OASI depletion pulled to 2032
Market Pulse
AI
5 events
AI equities face a funding-and-timing reality check as dilution plans and risk rotation hit leaders despite continued hyperscaler infrastructure buildout.
Latest Development
Super Micro disclosed $7B equity financing for near-term AI server component purchases, split between a $5B underwritten common offering and a $2B ATM expected to start in July.
A volatile tech pullback saw the Nasdaq close about 1% lower after a 3.7% intraday drop, with the semiconductor index down 1.9% and VIX touching 23.34.
Meta said it will lease a 168MW AI-enabled data center in Jamnagar, India from Reliance, with Reliance building the facility for delivery within two years and an option to scale.
Apple introduced Apple Intelligence and an LLM-based Siri refresh, but provided no firm general-availability release date; developers can test via beta and Siri AI beta is expected later this year.
SoftBank fell after a report that its plan to raise at least $6B via a margin loan backed by its OpenAI stake hit a snag, prompting exploration of alternative funding options.
Market reaction
AI/tech traded risk-off: Nasdaq -1% (after -3.7% intraday), SOX -1.9%, and VIX hit 23.34; single names slid on catalysts including SMCI about -9% in extended trade, AAPL down more than 3% post-WWDC, and SoftBank about -8.3% on financing headlines.
Our view
Near-term AI beta stays choppy as equity financing needs, crowded positioning, and delivery/monetization timelines dominate price discovery. Next watch is how quickly issuers tap funding (including SMCI’s ATM) and whether flagship product rollouts provide clearer timing and monetization signals.
What could change our view
Financing terms come in cleaner than feared, easing dilution and liquidity concerns.
Volatility falls sharply, reversing rotation and pulling high-duration AI back higher.
Tickers: $SMCI, $QQQ, $META, $AAPL
U.S.-Iran War
3 events
U.S.–Iran strikes and retaliatory launches keep Hormuz shipping in focus, with crude prices whipping between escalation risk and normalization signals.
Latest Development
CENTCOM said it completed self-defense strikes on Iranian air-defense, ground-control, and radar sites near the Strait of Hormuz after a U.S. Army Apache helicopter was shot down.
Iran launched multiple missiles and drones toward regional targets; Jordan reported five interceptions, Bahrain and Kuwait activated air defenses, and a U.S. official said nearly all inbound threats were intercepted without U.S. personnel injuries.
U.S. Energy Secretary Wright said Strait of Hormuz ship traffic is rising “very meaningfully,” while IMF PortWatch still showed a roughly five-ship 7-day average and shipping data cited increased AIS-off (“dark”) transits.
Market reaction
Crude traded headline-to-headline: Brent spiked to about $93.26 then reversed to roughly $91.2–$91.5, and WTI ran to about $90 before sliding back near $88.1–$88.3; earlier, Brent settled around $91.45 (-3%) and WTI around $88.20 (-3.4%).
Our view
Crude holds a volatile risk premium but stays range-bound as long as Hormuz transits continue recovering and retaliatory salvos remain largely intercepted. Watch for verified damage to Gulf production/ports or a renewed slide in tracked ship arrivals that would force a repricing of disruption odds.
What could change our view
Successful missile/drone strikes causing casualties or material U.S. base damage.
Hormuz traffic fails to rebound as PortWatch stays depressed and dark transits surge.
Tickers: $USO, $CL=F
Macro & Policy Digest
House advances immigration enforcement funding toward Trump’s desk and passes a pro-union first-contract bill setting up crosscurrents for contractors and labor-intensive sectors.
Latest Development
The House passed a $70B immigration enforcement package 214–212 after Senate approval, allocating about $38B for ICE and $26B for CBP through FY2029, and it now awaits President Trump’s signature.
The House passed the Faster Labor Contracts Act 230–193 via a discharge petition, requiring first-contract bargaining within 10 days of a union request and shifting unresolved disputes to mediation and potential arbitration after 90 days.
Our view
The immigration funding bill is likely to be signed, supporting enforcement and detention-linked beneficiaries while remaining a modest macro impulse. The labor bill is a nearer-term overhang for labor-intensive sectors only if it shows a credible path beyond the House; monitor follow-on legislative progress and implementation timelines.
What could change our view
Trump signature is delayed or withheld, undermining enforcement-linked revenue expectations.
First-contract bill advances beyond the House, accelerating labor-cost repricing risk.
Tickers: $GEO, $SPY
China May inflation shows producer-price acceleration from input-cost shocks while consumer inflation softens, raising margin-pressure concerns for manufacturers.
Latest Development
China’s May PPI rose 3.9% y/y (highest since July 2022) as CPI came in 1.2% y/y and -0.1% m/m; officials cited Middle East-linked input costs and AI capex demand.
Market reaction
Around the release, CSI 300 fell about 1% and Hang Seng slipped 0.8%, while China’s 10-year government yield was little changed near 1.740%.
Our view
Treat the print as supply-driven reflation that supports upstream input pricing but keeps pressure on downstream margins and demand-sensitive exposures (e.g., FXI). Watch whether PPI strength persists alongside subdued CPI, which would reinforce a cost-push mix rather than broad-based consumption reacceleration.
What could change our view
A rebound in CPI momentum that signals demand-led inflation and stronger pricing power.
Rapid easing in energy/metal input costs that pulls PPI down quickly.
Tickers: $FXI
Social Security trustees pull forward OASI depletion to late 2032, sharpening fiscal-policy pressure while keeping long-duration rates sensitive to Washington headlines.
Latest Development
The SSA trustees report now projects the OASI retirement trust fund depletes in late 2032 (three months earlier), implying about 78% of scheduled benefits payable; combining OASI with DI could extend full benefits to Q3 2034 but needs Congress.
Our view
This is primarily a slow-burn U.S. fiscal headline that raises the odds of renewed solvency negotiations without an immediate policy outcome. Monitor for concrete Congressional action on fund reallocation or benefit-tax changes tied to the recent tax law that could materially shift the financing path.
What could change our view
Congress moves quickly on solvency legislation, changing expected benefit and revenue trajectories.
Benefit-tax changes prove larger than expected, materially altering trust fund projections.
Tickers: $TLT
Company Events
Biopharma tape set for split single-name moves as Sanofi halts a CIDP Phase 3 on futility and Cellectis wins FDA RMAT.
Latest Development
Sanofi will stop the MOBILIZE Phase 3 riliprubart trial in refractory CIDP after an independent interim futility review, citing no new safety signal and guiding no change to 2026 financial guidance.
FDA granted Cellectis RMAT designation for lasme-cel, a CD22 allogeneic CAR-T in relapsed/refractory B-ALL; final Phase 1 BALLI-01 data are scheduled for oral presentation at EHA on June 13.
Our view
Idiosyncratic volatility: SNY sentiment stays cautious after the futility stop while attention shifts to whether the VITALIZE Phase 3 continues, and CLLS trades more on the June 13 efficacy/safety readout. We monitor Sanofi’s decision on other riliprubart studies and whether EHA details support a credible registrational path under RMAT.
What could change our view
Sanofi halts or delays VITALIZE, implying broader riliprubart program failure.
EHA data show weaker responses or safety issues, undermining lasme-cel momentum.
Tickers: $SNY, $CLLS
SpaceX’s fixed-price $135 IPO with a targeted 30% retail allocation shifts focus to allocations and could drive volatile Friday trading.
Latest Development
SpaceX is marketing an IPO at a non-range $135 price, aiming to allocate about $75B of shares before expected Friday trading, with orders reportedly stopping Wednesday and retail targeted near 30% via major broker platforms.
Our view
The fixed-price structure makes allocation outcomes the primary driver, raising odds of large first-day gaps and intraday swings around Friday’s debut. Watch Wednesday order cutoff and Thursday allocation mapping for signals on allocation tightness, especially given the unusually large targeted retail slice.
What could change our view
Orders stay open longer or allocations prove loose, damping debut volatility.
Retail allocation target is reduced materially, cutting broker-driven flow expectations.
Tickers: $TSLA
Pentagon adds Alibaba and Baidu to the DoD 1260H list, lifting procurement and reputational overhang as indirect sourcing restrictions loom in 2027.
Latest Development
DoD updated its Section 1260H “Chinese military companies” list, adding Alibaba, Baidu and BYD; direct DoD contracting is barred later this month, with third-party procurement bans starting June 2027.
Market reaction
ADRs moved modestly on the news: BIDU fell 2.1% and BABA 0.8%, while BYD was down 0.8% in the referenced session.
Our view
The 1260H designation stays a procurement-restriction issue rather than a broader sanctions regime, keeping the immediate fundamental hit to BABA/BIDU limited but sustaining a valuation discount. Monitor whether U.S. primes and integrators proactively de-risk supply chains ahead of the later-this-month contracting cutoff and the June 2027 indirect sourcing ban.
What could change our view
Escalation from 1260H listing into Treasury sanctions or broader U.S. restrictions.
Faster-than-expected supply-chain de-risking by defense contractors hits commercial demand.
Tickers: $BABA
Cybersecurity bids look supported as CrowdStrike highlights accelerating China-linked espionage against AI assets, reinforcing spend priority for endpoint, identity, and incident response.
Latest Development
CrowdStrike says China-nexus actors drove over 58% of state-sponsored targeted attacks on tech firms in the 12-month period to Mar. 31, with heightened focus on AI IP and persistent-access exploitation.
Our view
Rising AI-asset targeting sustains security budget urgency, supporting demand momentum across endpoint monitoring, identity/workforce controls, and incident response vendors. Watch for customer disclosures of AI-infrastructure breach activity or workforce-infiltration attempts, which would accelerate near-term spend reprioritization.
What could change our view
Enterprise security budgets soften, delaying endpoint and identity upgrades despite threat headlines.
Material reduction in AI-targeted espionage indicators undermines urgency for incremental spend.
Tickers: $CRWD
Brookfield teams with Mitsubishi HC Capital to scale a contracted European renewables platform, seeded with 570MW and ~€400M equity value targeting a 2H26 launch.
Latest Development
Brookfield Asset Management and Mitsubishi HC Capital formed a jointly controlled JV to acquire and operate contracted European renewables, seeded with ~570MW across six countries at ~€400M equity value, launching 2H26 pending approvals.
Our view
This is a steady, fee-friendly platform build for BAM, emphasizing contracted cash flows and optionality for follow-on acquisitions rather than a near-term earnings catalyst. Monitor regulatory/closing progress and whether the partners commit incremental capital to accelerate acquisitions ahead of the 2H26 launch.
What could change our view
Regulatory approvals or closing conditions delay or block the planned 2H26 launch.
Acquisition pipeline or pro rata funding appetite weakens, limiting platform scale-up.
Tickers: $BAM
Go deeper -
For intraday developments, follow our Midday posts.
For the close, the wrap, and next-day trade ideas, read the Evening Memo.
For deeper work, Forward Valuation covers multi-week single-name setups (paid subscribers only).
Deep Dive is where we publish our full thematic research for paid subscribers.
Informational only; not investment advice. Sources deemed reliable.